TNF inhibitors should be used in patients with heart failure only after consideration of other treatment options.
Contra-indicated in patients with sepsis.
TNF inhibitors are contra-indicated in patients with a personal or family history of multiple sclerosis or demyelinating disease.
TNF inhibitors should not be administered to patients with moderate to severe heart failure (New York Heart Association Functional Class III/IV).
Etanercept-szzs (Erelzi) is biosimilar to Etanercept (Enbrel). Approved 08/30/2016
Etanercept-ykro (Eticovo) ) is biosimilar to Etanercept (Enbrel). Approved 04/25/2019
- TRADE NAMES: Enbrel (Amgen); Erelzi (Sandoz)
- INDICATIONS: Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged 2 years or older, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis
- CLASS: Anti-Tumor Necrosis Factor-alpha (TNF-α antagonist), Antipsoriatic agent, Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), Cytokine inhibitor, Disease-modifying antirheumatic drug (DMARD)
- HALF-LIFE: 4–13 days
- FDA APPROVAL DATE: 7/24/2003
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Anakinra, Cyclophosphamide, Live vaccines
SERIOUS INFECTIONS AND MALIGNANCIES
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of etanercept in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/28/2024
